Low-dose IL-2 therapy invigorates CD8+ T cells for viral control in systemic lupus erythematosus.
Autor: | Pengcheng Zhou, Jiali Chen, Jing He, Ting Zheng, Joseph Yunis, Victor Makota, Yannick O Alexandre, Fang Gong, Xia Zhang, Wuxiang Xie, Yuhui Li, Miao Shao, Yanshan Zhu, Jane E Sinclair, Miao Miao, Yaping Chen, Kirsty R Short, Scott N Mueller, Xiaolin Sun, Di Yu, Zhanguo Li |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: | |
Zdroj: | PLoS Pathogens, Vol 17, Iss 10, p e1009858 (2021) |
Druh dokumentu: | article |
ISSN: | 1553-7366 1553-7374 |
DOI: | 10.1371/journal.ppat.1009858 |
Popis: | Autoimmune diseases are often treated by glucocorticoids and immunosuppressive drugs that could increase the risk for infection, which in turn deteriorate disease and cause mortality. Low-dose IL-2 (Ld-IL2) therapy emerges as a new treatment for a wide range of autoimmune diseases. To examine its influence on infection, we retrospectively studied 665 patients with systemic lupus erythematosus (SLE) including about one third receiving Ld-IL2 therapy, where Ld-IL2 therapy was found beneficial in reducing the incidence of infections. In line with this clinical observation, IL-2 treatment accelerated viral clearance in mice infected with influenza A virus or lymphocytic choriomeningitis virus (LCMV). Noticeably, despite enhancing anti-viral immunity in LCMV infection, IL-2 treatment exacerbated CD8+ T cell-mediated immunopathology. In summary, Ld-IL2 therapy reduced the risk of infections in SLE patients and enhanced the control of viral infection, but caution should be taken to avoid potential CD8+ T cell-mediated immunopathology. |
Databáze: | Directory of Open Access Journals |
Externí odkaz: |